A recent study conducted by Jelena M. Pavlovic, MD, PhD, and colleagues at Albert Einstein College of Medicine found that migraine is one of the most debilitating medical conditions worldwide. Patients with migraine prioritize the rapid onset of treatment effect. The researchers conducted a phase 2/3 study on 603 adults with acute migraines. Participants used a 10 mg zavegepant nasal spray as needed for migraine attacks for a period of 52 weeks. The study allowed previously prescribed treatments alongside the nasal spray. The efficacy of the treatment was measured using the Migraine-Specific Quality-of-Life questionnaire. The results showed that after 12 weeks, there was a significant improvement in all three domains of quality of life: restrictive role function, preventive role function, and emotional function. At week 52, the improvements in these domains were even greater. The mean scores for restrictive role function, preventive role function, and emotional function were 70.5, 82.5, and 80.2, respectively. Overall, the study concluded that long-term treatment with zavegepant nasal spray led to improvements in migraine-specific quality of life. This research provides valuable insights into the potential benefits of this treatment option for patients suffering from acute migraines.

To know more: About the original article click here.